MX2018011760A - Aducto de ciclodextrina-panobinostat. - Google Patents
Aducto de ciclodextrina-panobinostat.Info
- Publication number
- MX2018011760A MX2018011760A MX2018011760A MX2018011760A MX2018011760A MX 2018011760 A MX2018011760 A MX 2018011760A MX 2018011760 A MX2018011760 A MX 2018011760A MX 2018011760 A MX2018011760 A MX 2018011760A MX 2018011760 A MX2018011760 A MX 2018011760A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclodextrin
- panobinostat
- aqueous solution
- adduct
- panobinostat adduct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
Abstract
La presente invención proporciona un método para producir un aducto de ciclodextrina-panobinostat, el cual comprende: a) proporcionar una primera solución acuosa conformada por un agente tampón; dicha solución tiene un pH en un rango de 2.0 a 4.0; b) disolver el panobinostat en la primera solución acuosa mencionada para generar una segunda solución acuosa; y c) mezclar la segunda solución acuosa mencionada que contiene panobinostat con una tercera solución acuosa con ciclodextrina, con el fin de formar una cuarta solución compuesta por un aducto de ciclodextrina panobinostat. Asimismo, se proporciona una solución de líquido cefalorraquídeo artificial (LCR) compuesto por el aducto de ciclodextrina-panobinostat, así como las aplicaciones médicas del aducto de ciclodextrina-panobinostat, incluyendo el tratamiento contra tumores cerebrales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201605406 | 2016-03-31 | ||
GBGB1610440.8A GB201610440D0 (en) | 2016-06-15 | 2016-06-15 | Pharmaceutical formulations |
PCT/EP2017/057472 WO2017167837A1 (en) | 2016-03-31 | 2017-03-29 | Cyclodextrin-panobinostat adduct |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011760A true MX2018011760A (es) | 2019-02-20 |
Family
ID=58489304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011760A MX2018011760A (es) | 2016-03-31 | 2017-03-29 | Aducto de ciclodextrina-panobinostat. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10722597B2 (es) |
EP (1) | EP3347055B1 (es) |
JP (1) | JP6880058B2 (es) |
KR (1) | KR102416050B1 (es) |
CN (1) | CN109310783B (es) |
AU (2) | AU2017242544B2 (es) |
BR (1) | BR112018069901A2 (es) |
CA (1) | CA3018923A1 (es) |
ES (1) | ES2743740T3 (es) |
MX (1) | MX2018011760A (es) |
PL (1) | PL3347055T3 (es) |
PT (1) | PT3347055T (es) |
WO (1) | WO2017167837A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3030142A1 (en) * | 2016-07-08 | 2018-01-11 | Ranedis Pharmaceuticals, Llc | Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases |
EP3560492B1 (en) | 2016-12-26 | 2023-11-29 | FUJIFILM Corporation | Lipid particle composition and pharmaceutical composition |
GB202020359D0 (en) | 2020-12-22 | 2021-02-03 | Midatech Pharma Wales Ltd | Pharmaceutical compositions and use thereof in combination therapy for brain cancer |
WO2024041744A1 (en) | 2022-08-26 | 2024-02-29 | Biodexa Ltd. | Combination therapy for brain cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001278705A1 (en) | 2000-08-10 | 2002-02-25 | Takeda Chemical Industries Ltd. | Pharmaceutical composition |
KR101329437B1 (ko) | 2005-05-13 | 2013-11-14 | 토포타겟 유케이 리미티드 | Hdac 억제제의 약학 제형 |
JP2009535360A (ja) | 2006-04-26 | 2009-10-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 高分子量神経治療薬の対流増加送達のための組成物および方法 |
CN101478959A (zh) | 2006-06-26 | 2009-07-08 | 诺瓦提斯公司 | 有机化合物 |
ITRM20070038A1 (it) * | 2007-01-26 | 2008-07-27 | Uni Degli Studi Di Roma La Sapienza | Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico |
CL2008002786A1 (es) * | 2007-09-20 | 2009-05-15 | Novartis Ag | Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion. |
GB201204263D0 (en) * | 2012-03-12 | 2012-04-25 | Renishaw Plc | Giloma treatment |
WO2015191931A1 (en) * | 2014-06-12 | 2015-12-17 | University Of Notre Dame Du Lac | Composition and method for the treatment of neurological diseases and cerebral injury |
GB201601773D0 (en) | 2016-02-01 | 2016-03-16 | Renishaw Plc | Method |
-
2017
- 2017-03-29 ES ES17715654T patent/ES2743740T3/es active Active
- 2017-03-29 US US16/081,694 patent/US10722597B2/en active Active
- 2017-03-29 KR KR1020187029287A patent/KR102416050B1/ko active IP Right Grant
- 2017-03-29 MX MX2018011760A patent/MX2018011760A/es active IP Right Grant
- 2017-03-29 AU AU2017242544A patent/AU2017242544B2/en active Active
- 2017-03-29 WO PCT/EP2017/057472 patent/WO2017167837A1/en active Application Filing
- 2017-03-29 EP EP17715654.4A patent/EP3347055B1/en active Active
- 2017-03-29 CA CA3018923A patent/CA3018923A1/en active Pending
- 2017-03-29 PL PL17715654T patent/PL3347055T3/pl unknown
- 2017-03-29 JP JP2018550588A patent/JP6880058B2/ja active Active
- 2017-03-29 PT PT17715654T patent/PT3347055T/pt unknown
- 2017-03-29 BR BR112018069901A patent/BR112018069901A2/pt active IP Right Grant
- 2017-03-29 CN CN201780021581.9A patent/CN109310783B/zh active Active
-
2020
- 2020-06-11 US US16/899,408 patent/US11235068B2/en active Active
-
2023
- 2023-02-23 AU AU2023201091A patent/AU2023201091A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112018069901A2 (pt) | 2019-02-05 |
AU2017242544B2 (en) | 2022-11-24 |
US10722597B2 (en) | 2020-07-28 |
WO2017167837A1 (en) | 2017-10-05 |
US20200368367A1 (en) | 2020-11-26 |
KR20180125994A (ko) | 2018-11-26 |
AU2023201091A1 (en) | 2023-03-23 |
EP3347055A1 (en) | 2018-07-18 |
ES2743740T3 (es) | 2020-02-20 |
PL3347055T3 (pl) | 2019-11-29 |
US20190151468A1 (en) | 2019-05-23 |
EP3347055B1 (en) | 2019-06-12 |
AU2017242544A1 (en) | 2018-09-20 |
KR102416050B1 (ko) | 2022-07-01 |
JP6880058B2 (ja) | 2021-06-02 |
CN109310783A (zh) | 2019-02-05 |
CN109310783B (zh) | 2022-06-17 |
JP2019513139A (ja) | 2019-05-23 |
US11235068B2 (en) | 2022-02-01 |
PT3347055T (pt) | 2019-09-13 |
CA3018923A1 (en) | 2017-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY197635A (en) | Benzooxazole derivatives as immunomodulators | |
MX2018011760A (es) | Aducto de ciclodextrina-panobinostat. | |
TW201614068A (en) | Fucosidase from bacteroides and methods using the same | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
CU24488B1 (es) | Nanopartículas terapéuticas que comprenden un ácido hidrófobo y un agente terapéutico útiles para diferentes tipos de cáncer y proceso de preparación de las mismas | |
CO7141410A2 (es) | Compuesto heterocíclico nitrogenado | |
MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
AR096893A1 (es) | Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
BR102014031070A2 (pt) | método de tratamento de uma formação subterrânea penetrada por um poço, e método para minimizar o sobredeslocamento de um propante a partir de uma formação subterrânea penetrada por um poço | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
EP3456815A4 (en) | AQUEOUS SOLUTION THAT CAN BE ADMINISTERED TO A LIVING BODY AND METHOD FOR ITS PRODUCTION | |
MX2017013680A (es) | Dispositivo de baño medico. | |
BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
MX2018008640A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. | |
MX2018005085A (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas. | |
EP3702470A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
MX2018006226A (es) | Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo. | |
MX2019000677A (es) | Células miméticas de células b. | |
MX2020006443A (es) | Combinacion de un retinoide y un extracto de silybum marianum (l.) gaertn. | |
WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |